GSK1278863: all 34 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)Not yet recruitingNCT07300111Phase 3
• Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)CompletedNCT05682326Phase 3Results posted
• Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy ParticipantsCompletedNCT04640311Phase 1Results posted
• Daprodustat Bioequivalence and Food Effect StudyCompletedNCT03493386Phase 1Results posted
• Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)CompletedNCT03457701Phase 2Results posted
• Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)TerminatedNCT03446612Phase 2Results posted
• Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)CompletedNCT03409107Phase 3Results posted
• Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)CompletedNCT03400033Phase 3Results posted
• Absorption and Elimination of Radiolabeled DaprodustatCompletedNCT03239522Phase 1Results posted
• Daprodustat Hepatic Impairment StudyCompletedNCT03223337Phase 1Results posted
• Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)CompletedNCT03029247Phase 2Results posted
• Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)CompletedNCT03029208Phase 3Results posted
• Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)CompletedNCT02879305Phase 3Results posted
• Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)CompletedNCT02876835Phase 3Results posted
• Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating AgentsCompletedNCT02829320Phase 3Results posted
• Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal AnemiaCompletedNCT02791763Phase 3Results posted
• Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating AgentCompletedNCT02689206Phase 2Results posted
• Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal DialysisCompletedNCT02243306Phase 1Results posted
• 3 Month PHI PAD PoM StudyCompletedNCT02135848Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With AnemiaTerminatedNCT02075463Phase 2Results posted
• Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney DiseaseCompletedNCT02019719Phase 2Results posted
• A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)CompletedNCT01977573Phase 2Results posted
• Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated AnemiaCompletedNCT01977482Phase 2Results posted
• Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm RepairCompletedNCT01920594Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863CompletedNCT01831804Phase 1Results posted
• 4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney DiseaseCompletedNCT01587924Phase 2Results posted
• 4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing DialysisCompletedNCT01587898Phase 2Results posted
• A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney DiseaseCompletedNCT05951192Phase 4
• Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult VolunteersCompletedNCT02371603Phase 1
• Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy VolunteersCompletedNCT02293148Phase 1
• GSK1278863 Effects on Eccentric Exercise-Induced Muscle DamageCompletedNCT02231190Phase 1
• Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy VolunteersCompletedNCT01673555Phase 1
• Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal ImpairmentTerminatedNCT01406340Phase 1
• Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)CompletedNCT01376232Phase 1

← GSK1278863 overview